Steroid 5α-reductase isozymes I and II in recurrent prostate cancer

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4365-4371

  Titus, Mark A ^a,e   Gregory, Christopher W ^a,d   Ford III, O Harris ^a   Schell, Michael J ^a   Maygarden, Susan J ^a   Mohler, James L ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Voyager Pharmaceutical Corporation   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ISOENZYME; POLYCLONAL ANTIBODY; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE I; STEROID 5ALPHA REDUCTASE II; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; ENZYME INHIBITION; GENE LOSS; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RECURRENT CANCER; TISSUE MICROARRAY; CELL NUCLEUS; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CELL NUCLEUS; CYTOPLASM; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; TISSUE ARRAY ANALYSIS;

EID: 20444476601     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0738     Document Type: Article

References (50)

1. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-8.
2. Hsing AW, Reichardt JKV, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35.
3. Balanger B, Balanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat, guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32:695-8.
4. Russell DW, Wilson JD. Steroid 5α-reductase: two genes two enzymes. Annu Rev Biochem 1994;63:25-61.
5. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
6. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
7. Huggins CB, Stephens RC, Hodges CV. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-12.
8. De Vere White R, Meyers F, Chi SG, et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997;31:1-6.
9. Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998;35:63-70.
10. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
11. Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718-24.
12. Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systemic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20:6718-23.
13. Visakorpi T, Hytinen E, Koivist P, et al. In vivo amplification of the androgen receptor gene in progression of human prostate cancer. Nat Genet 1995;9:401-6.
14. Culig Z, Hobisch A, Bartsch G, Klocker H. Expression and function of androgen receptor in carcinoma of the prostate. Microsc Res Tech 2000;51:447-55.
15. Tan J-A, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptor expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-9.
16. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
17. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
18. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
19. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
21. Kim D, Gregory CW, Smith GJ, Mohler JL. Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 1999;35:2-10.
22. Thomas LN, Douglas RC, Vessey JP, et al. 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003;170:2019-25.
23. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992;147:1293-7.
24. Miyamoto KK, McSherry SA, Dent GA, et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993;149:1015-9.
25. Moore RJ, Wilson JD. Reduced nicotinamide adenine dinucleotide phosphate: δ-4-3-ketosteroid 5α-oxidoreductase. Methods Enzymol 1975;36:466-74.
26. Lowry OH, Rosebrough NJ, Farr AL, Randell RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
27. Steckelbroeck S, Watzka M, Reichelt R, et al. Characterization of the 5α-reductase-3-hydroxysteroid dehydrogenase complex in the human brain. J Clin Endocrinol Metab 2001;86:1324-31.
28. Aumuller G, Eicheler W, Renneberg H, Adermann K, Vilja P, Forssman WG. Immunocytochemical evidence for differential subcellular localization of 5α-reductase isoenzymes in human tissues. Acta Anat (Basel) 1996;156:241-52.
29. Bonkhoff H, Stein U, Aumuller G, Remberger K. Differential expression of 5α-reductase isoenzymes in human prostate and prostatic carcinomas. Prostate 1996;29:261-7.
30. Brendler CB, Follansbee AL, Isaacs JT. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. J Urol 1985;133:495-501.
31. Shirakawa T, Okada H, Acharya B, et al. Messenger RNA levels and enzyme activities of 5α-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 2004;58:33-40.
32. Soderstrom TG, Bjelfman C, Brekkan E, et al. Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 2001;86:855-8.
33. Pratis K, O'Donnell L, Ooi GT, McLachian RI, Robertson DM, Enzyme assay for 5α-reductase type 2 activity in the presence of 5α-reductase type I activity in rat testis. J Steroid Biochem Mol Biol 2000;75:75-82.
34. Weingartner K, Ben-Sasson SA, Stewart R, Richie JP, Riedmiller H, Folkman J. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. J Urol 1998;159:465-70.
35. Salomao DR, Graham SD, Bostwick DB. Microvascularization invasion of prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 1995;119:1050-4.
36. Mabjeesh NJ, Willard MT, Frederickson CE, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416-25.
37. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
38. Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
39. Kaluzova M, Kaluz S, Stanbridge EJ. High cell density induces expression from the carbonic anhydrase 9 promoter. Biotechniques 2004;36:228-34.
40. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996;14:176-86.
41. Jin Y, Penning TM. Steroid 5-reductases and 3-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab 2001;15:79-94.
42. Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997;31:118-24.
43. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972;34:730-5.
44. Eisenberger MA, Laufer M, Vogelzang NJ, et al. Phase I and clinical pharmacology of a type I and II, 5-α-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology 2004;63:114-9.
45. Kim IY, Kim B-C, Seong DH, et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002;62:5365-9.
46. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman WI, Pienta KJ. A phase II trial of oral diethylstielbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257-60.
47. Liehr JG. Genotoxic effects of estrogens. Mutat Res 1990;238:269-76.
48. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165-72.
49. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995;154:1642-6.
50. Roehrborn CG, Boyle J, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.